Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.

@article{citeulike:2520222, abstract = {A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world.}, author = {Ramessar, K. and Rademacher, T. and Sack, M. and Stadlmann, J. and Platis, D. and Stiegler, G. and Labrou, N. and Altmann, F. and Ma, J. and St\"{o}ger, E. and Capell, T. and Christou, P.}, citeulike-article-id = {2520222}, doi = {10.1073/pnas.0708841104}, issn = {1091-6490}, journal = {Proceedings of the National Academy of Sciences of the United States of America}, keywords = {hiv, microbicide, molecular\_farming, pharmaplanta, pharming}, month = {March}, number = {10}, pages = {3727--3732}, posted-at = {2008-05-06 08:38:37}, priority = {2}, title = {Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.}, url = {http://dx.doi.org/10.1073/pnas.0708841104}, volume = {105}, year = {2008} }

TY - JOUR ID - citeulike:2520222 L3 - citeulike-article-id:2520222 N2 - A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world. IS - 10 JF - Proceedings of the National Academy of Sciences of the United States of America SN - 1091-6490 EP - 3732 TI - Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. VL - 105 SP - 3727 KW - hiv KW - microbicide KW - molecular_farming KW - pharmaplanta KW - pharming AU - Ramessar, K AU - Rademacher, T AU - Sack, M AU - Stadlmann, J AU - Platis, D AU - Stiegler, G AU - Labrou, N AU - Altmann, F AU - Ma, J AU - Stöger, E AU - Capell, T AU - Christou, P PY - 2008/03/11/ UR - http://dx.doi.org/10.1073/pnas.0708841104 ER -